Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 3, 2003, Pages 205-208

  Anjaneyulu, M ^a,b   Ramarao, P ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Multiple low dose streptozotocin; Pioglitazone; PPAR ; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STREPTOZOCIN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; NONHUMAN; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HYPOGLYCEMIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037986447     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2003.25.3.769641     Document Type: Article

References (27)

1. Foulis, A.K. The pathogenesis of β cells destruction in Type 1 (insulin-dependent) diabetes mellitus. J Pathol 1987, 152: 141-68.
2. Gepts, W., LeCompe, P.M. The pathology of type I diabetes. In: The Diabetes Pancreas. Yolk, B.W., Arquilla, E.R. (Eds.). New York NY 1985, 337-65.
3. Like, A.A., Rossini, A.A. Streptozotocin-induced pancreatic insulitis; New model of diabetes mellitus. Science 1976, 193: 415-17.
4. Hofmann, C.A., Colca, J.R. New oral thiazolidinediones antidiabetic agents act as insulin sensitizers. Diabetes care 1992, 15: 1075-8.
5. Nicholas, C.T. New therapeutic agents for the treatment of insulin resistance and NIDDM. DDT 1996, 1: 109-16.
6. Yoshioka, S., Nishino, H., Shirakit, T. et al. Antihypertensive effect of CS-045 treatment in obese Zucker rats. Metabolism 1993, 42: 75-80.
7. Keller, H., Wahli, W. Peroxisome Proliferator-activated receptors. Trends Endocrinal Metab 1993, 4: 291-6.
8. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., Spiegelman, B.M. mPPAR-γ2 tissue specific regulator of an adipocyte enhancer. Genes Dev 1994, 8: 1224-34.
9. Tontonoz, P., Hu, E., Spiegelman, B.M. Stimulatian of adipogenesis in fibroblasts by PPAR-γ2, a lipid-activated transcription factor. Cell 1994, 79: 1147-56.
10. 2 is a ligand for adipocyte determination factor PPAR-γ. Cell 1995, 83(5): 803-12.
11. 2 metabolize binds Peroxisome proliferator-activated receptor beta and promotes adipocyte differentiation. Cell 1995, 83: 813-19.
12. Takamura, T., Ando, H., Nagai, Y., Yamashita, H., Nohara, E., Kobayashi, K. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 1999, 44: 107-14.
13. Rerup, C., Tarding, F. Streptozotocin and alloxan diabetes in mice. Eur J Pharmacol 1969, 7: 89-96.
14. Schein, P.S., Bates, R.W. Plasma glucose levels in normal and adrenalectomized mice treated with streptozotocin and nicotinamide. Diabetes 1968, 17: 760-5.
15. Schein, P.S., Coonny, D.A., Yerson, M.L. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 1967, 27: 2824-32.
16. Banisinath, M., Ramabadran, K., Turndorf, H., Puig, M.M. Effect of acute and chronic hyperglycemia on morphine-induced inhibition of gastrointestinal tract in mice. Pharmacology 1988, 37: 281-5.
17. Schmidt, F.H. Methodon der harn-und blutzuckerbestimmung II. Handbuch des. Diabetes Mellitus 1971, 2: 938-51.
18. Mayer, B.R., Katze, H.L., Eschbach, J. et al. Transdermal deliver of human insulin to albino rabbits using electrical current. Amer J Med Sci 1989, 297: 321-6.
19. Kolb, H., Kroncke, K.D. IDDM, lessons from the low dose of streptozotocin model in mice. Diabetes Rev 1993, 1: 116-26.
20. Beales, P.E., Liddi, R., Giorgini, A.E. Troglitazone prevents insulin dependent diabetes in the none-obese diabetes mouse. Eur J Pharmacol 1988, 357: 221-5.
21. Yoshioka, T, Fujita, T., Kanai, T. Studies on hindered phenol and analogues I, Hypolipidemic and hypoglycemic agents with ability to inhibit lipidperoxidation. J Med Chem 1989, 32: 421-8.
22. Noguchi, N., Sakai, H., Kato, Y. Inhibition of oxidation of low-density lipoprotein by troglitazone. Atherosclerosis 1996, 123: 227-34.
23. Mendola, J., Wright, J.R., Lacy, P.E. Oxygen free radical scavenger and immune destruction of murine islets in allograft rejection and multiple low dose streptozotocin induced insulitis. Diabetes 1989, 38: 379-85.
24. Heineke, E.W., Johnson, M.B., Dillberger, J.E., Robinson, K.H. Antioxidant MDL 29311 prevents diabetes in non-obese diabetic and multiple low-dose STZ-injected mice. Diabetes 1993, 42: 1721-30.
25. Skyler, J.S., Marke, J.B. Immune intervention. In: Diabetes Mellitus. LeRpith D., Taylor S.I., Olefsky J.M. (Eds.). Lippincott-Raven: Philadelphia 1996, 402-8.
26. Kobayashi, T., Tamemoto, K., Nakanishi, K. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993, 16: 780-8.
27. Zimmet, P.Z., Tumi, T., Mackay, I.R. Latent autoimmuue diabetes mellitus in adult (LADA), The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin deficiency. Diabetes Med 1994, 11: 299-303.